Sign in Subscribe

kras

A collection of 116 issues

Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer The phase 3 ANCHOR trial (NCT04854668) compared CapeOX chemotherapy combined with anlotinib versus CapeOX combined with bevacizumab in patients with RAS/BRAF wild-type mCRC, evaluating

Plant-derived formulation disrupts metabolism in KRAS-mutant colorectal and pancreatic cancer cells

Skip to content The CRC Digest Plant-derived formulation disrupts metabolism in KRAS-mutant colorectal and pancreatic cancer cells A Lepidium latifolium formulation induced cell death and metabolic disruption in KRAS-mutant cancer models through iron-dependent mechanisms. (Molecules) This content is informational only and does not constitute medical advice. Always consult your oncologist

Subscribe to The CRC Digest

Sign up now to get access to the library of members-only issues.
jamie@example.com
Subscribe

The CRC Digest provides research summaries for informational and educational purposes only.
This is not medical advice. Always consult your healthcare provider before making any decisions about your care.

Disclaimer Privacy Policy Terms of Use About